Proteomics Market Report

To learn more about this report, Download Free Sample Report

Global Proteomics Market Size 

The Global Proteomics Market is projected to grow from USD 27.36 billion in 2025 to USD 30.60 billion in 2026 and reach USD 74.79 billion by 2034, registering a CAGR of 11.82% during the forecast period from 2026 to 2034.

MARKET DRIVERS

Increasing Prevalence of Chronic Diseases and Cancer Research

The rising global burden of chronic diseases, particularly cancer, mainly fuels the global proteomics market expansion. According to the World Health Organization, cancer accounts for nearly 10 million deaths annually worldwide, necessitating advanced diagnostic tools and targeted therapies. Proteomics plays a pivotal role in identifying specific protein biomarkers associated with tumor progression and metastasis. According to the American Cancer Society, early detection can improve survival rates by up to 90% for certain types of cancer. This statistic highlights the critical importance of sensitive proteomic assays in screening programs. Researchers utilize mass spectrometry to analyze protein expression profiles in patient samples, enabling the discovery of novel diagnostic markers. Pharmaceutical companies rely on these insights to develop precision medicines that target specific molecular pathways. The shift toward personalized oncology drives demand for high-throughput proteomic platforms capable of processing large clinical cohorts. Government funding for cancer research initiatives further accelerates the adoption of proteomic technologies in academic and clinical laboratories. As the understanding of protein dysregulation in disease deepens, the integration of proteomics into routine clinical practice becomes increasingly viable. This trend ensures sustained investment in innovative proteomic solutions and instrumentation.

Advancements in Mass Spectrometry and Analytical Technologies

Technological innovations in mass spectrometry and related analytical techniques further contribute to the proteomics market growth. According to the Journal of Proteome Research, recent developments in tandem mass spectrometry have improved peptide identification rates by over 50% compared to previous generations. These improvements allow researchers to detect low-abundance proteins and post-translational modifications with greater precision. According to the Association for Biomolecular Resource Facilities, the integration of artificial intelligence with proteomic data analysis has reduced processing time by 40%. This efficiency gain enables larger-scale studies and faster turnaround times for clinical applications. Manufacturers are introducing compact and user-friendly mass spectrometers that lower the barrier to entry for smaller laboratories. The ability to perform real-time monitoring of protein interactions supports dynamic biological studies. Enhanced software algorithms facilitate the interpretation of complex datasets, making proteomics more accessible to non-specialist researchers. These technological strides expand the applicability of proteomics beyond basic research into drug development and clinical diagnostics. As instruments become more robust and cost-effective, adoption rates increase across diverse scientific disciplines. This continuous innovation cycle drives replacement sales and upgrades within existing infrastructure.

MARKET RESTRAINTS

High Cost of Instrumentation and Reagents

The substantial financial investment required for acquiring and maintaining advanced proteomic equipment hampers the proteomics market growth. According to the Nature Methods journal, a high-resolution mass spectrometer can cost between 500,000 and 1 million dollars, posing a barrier for small academic institutions and start-ups. These high upfront costs limit the accessibility of state-of-the-art proteomic technologies to well-funded organizations. According to the American Society for Biochemistry and Molecular Biology, annual maintenance contracts and specialized reagents can add 15% to 20% to the total cost of ownership. This ongoing financial burden discourages some laboratories from expanding their proteomic capabilities. Budget constraints often force researchers to rely on core facilities with limited availability, causing delays in project timelines. The high cost of consumables such as columns and solvents further increases the per-sample expense. Smaller biotechnology firms may struggle to justify the expenditure without immediate commercial returns. Consequently, many potential users delay purchases or opt for outsourcing services, which limits direct equipment sales. This economic barrier restricts market penetration in resource-constrained settings and slows the overall adoption rate of new proteomic technologies.

Complexity of Data Analysis and Interpretation

The intricate nature of proteomics data analysis further hinders the proteomics market growth. According to the European Bioinformatics Institute, a single proteomic experiment can generate terabytes of raw data, requiring substantial computational power and storage capacity. This data deluge overwhelms many research teams lacking specialized bioinformatics expertise. According to the Journal of Computational Biology, standardizing data formats and analysis pipelines remains a significant hurdle, with over 60% of studies using incompatible methods. This lack of uniformity hinders data sharing and reproducibility across different laboratories. The complexity of interpreting post-translational modifications and protein isoforms adds another layer of difficulty. Researchers often struggle to distinguish biological significance from technical noise in large datasets. Healthcare providers face challenges in integrating proteomic data with electronic health records for clinical decision-making. Without streamlined and user-friendly analysis tools, the value of proteomic insights remains underutilized. This analytical bottleneck restricts the translation of research findings into clinical applications. Addressing this complexity requires significant investment in software development and training.

MARKET OPPORTUNITIES

Integration of Proteomics in Precision Medicine

The growing emphasis on precision medicine is a notable opportunity for the proteomics market by enabling tailored therapeutic strategies. According to the National Academy of Medicine, proteomic profiling can identify patient-specific drug responses with an accuracy of over 80%, facilitating personalized treatment plans. This capability allows clinicians to select the most effective therapies while minimizing adverse effects. According to the Clinical Proteomic Tumor Analysis Consortium, proteogenomic approaches have led to the identification of new therapeutic targets in 30% of studied cancer cases. These discoveries drive pharmaceutical companies to incorporate proteomics into their drug discovery pipelines. The ability to monitor protein dynamics in real time supports adaptive treatment strategies. Hospitals are increasingly adopting proteomic tests for stratifying patients in clinical trials. Insurance providers are beginning to recognize the value of proteomic diagnostics in reducing long-term healthcare costs. Partnerships between technology vendors and healthcare systems facilitate the implementation of proteomic workflows. As regulatory agencies approve more proteomic-based diagnostic tests, the market expands into clinical routine. This integration transforms proteomics from a research tool into a critical component of modern healthcare delivery.

Expansion into Agricultural and Environmental Applications

The application of proteomic technologies in agriculture and environmental science offers a prominent opportunity for market diversification. According to the Food and Agriculture Organization of the United Nations, crop losses due to pests and diseases amount to 40% of global production, driving demand for proteomic-based resistance breeding. Researchers use proteomics to identify stress response proteins in plants, enabling the development of resilient crop varieties. According to the Environmental Protection Agency, proteomic biomarkers can detect water contamination levels with higher sensitivity than traditional chemical assays. This application supports environmental monitoring and public health safety initiatives. Agricultural biotechnology companies utilize proteomic data to optimize fertilizer usage and improve yield quality. The study of soil microbiomes through metaproteomics provides insights into nutrient cycling and ecosystem health. These non-clinical applications open new revenue streams for instrument manufacturers and service providers. Governments are investing in sustainable agriculture projects that leverage advanced biological tools. The versatility of proteomic platforms allows them to be adapted for diverse sample types. As awareness of food security and environmental protection grows, the demand for proteomic solutions in these sectors increases. This expansion reduces reliance on the healthcare sector and stabilizes market growth.

MARKET CHALLENGES

Lack of Standardization in Protocols and Procedures

The absence of universally accepted standards for proteomic workflows is a major challenge to the consistency and reliability of results in the proteomics market. According to the International Society of Advancement of Cytometry, variability in sample preparation protocols can lead to differences in protein identification rates of up to 50% between laboratories. This inconsistency undermines the comparability of research findings and hinders collaborative efforts. According to the Clinical and Laboratory Standards Institute, only 20% of clinical proteomic assays have undergone rigorous validation for routine diagnostic use. This lack of standardized validation criteria creates uncertainty among regulators and clinicians. Manufacturers face difficulties in developing instruments that cater to diverse and often conflicting protocol requirements. The absence of reference materials for quality control further complicates assay standardization. Researchers must invest significant time in optimizing methods for each specific study, reducing efficiency. Regulatory bodies hesitate to approve proteomic tests without established performance benchmarks. This regulatory ambiguity slows down the commercialization of new diagnostic products. Efforts to establish global standards are ongoing, but progress is slow. Until harmonization is achieved, the market will face barriers to widespread clinical adoption.

Shortage of Skilled Professionals and Expertise

The limited availability of trained professionals proficient in proteomic techniques and data analysis poses a significant challenge to the proteomics market. According to the American Society for Cell Biology, there is a deficit of over 10,000 qualified proteomics specialists globally, limiting the capacity of research institutions. This workforce gap restricts the number of projects that can be undertaken simultaneously and affects the quality of data interpretation. According to the Journal of Proteomics, training programs for advanced mass spectrometry and bioinformatics are limited in number and duration. The steep learning curve associated with complex instrumentation discourages new entrants into the field. Laboratories struggle to retain skilled staff due to high demand from industry and academia. The scarcity of experts means that many instruments operate below their full potential. Healthcare systems face difficulties in implementing proteomic services without adequate technical support. This limitation affects the speed of innovation and the translation of research into clinical practice. Educational institutions are slowly expanding curricula to address this gap, but the pipeline remains insufficient. Without a robust workforce, the market cannot fully realize its potential. Addressing this skills shortage requires coordinated efforts from industry, academia, and government.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Instrument Type Insights

The spectroscopy segment accounted for the leading share of the global proteomics market in 2025. The dominance of the spectroscopy segment in the global market can be credited to its unparalleled ability to identify and quantify proteins with high precision and sensitivity. According to the American Society for Mass Spectrometry, over 80% of proteomic research studies currently utilize mass spectrometry as the primary analytical tool, establishing it as the industry standard. This widespread adoption drives consistent demand for advanced instruments such as liquid chromatography-tandem mass spectrometers. According to the Journal of Proteome Research, modern high-resolution mass spectrometers can identify more than 10,000 proteins in a single run, providing comprehensive data for complex biological samples. This capability is essential for mapping the human proteome and understanding disease mechanisms. Researchers rely on these instruments for discovering biomarkers and validating drug targets. The versatility of spectroscopy allows it to be applied across various fields, including clinical diagnostics and basic research. Manufacturers continuously innovate by improving ionization sources and detectors to enhance performance. The integration of artificial intelligence with spectral analysis further boosts efficiency. As the complexity of biological questions increases, the need for robust spectroscopic solutions grows. This technological superiority ensures that spectroscopy remains the cornerstone of proteomic instrumentation. The recurring need for instrument upgrades and maintenance sustains long-term revenue streams for manufacturers.

On the other hand, the protein microarrays segment is estimated to register a promising CAGR of 15.4% over the forecast period owing to their high-throughput capabilities and cost-effectiveness. According to the National Institutes of Health, protein microarrays can analyze thousands of protein interactions simultaneously, significantly accelerating biomarker discovery processes. This efficiency appeals to pharmaceutical companies seeking to screen large compound libraries rapidly. According to the Nature Methods journal, the sensitivity of next-generation microarrays has improved by 50%, allowing for the detection of low-abundance proteins in small sample volumes. These advancements make microarrays suitable for clinical applications where sample availability is limited. The ability to perform multiplexed assays reduces reagent consumption and labor costs. Researchers are increasingly using microarrays for antibody profiling and autoimmune disease diagnosis. The miniaturization of array platforms enables integration with automated liquid handling systems. This automation enhances reproducibility and reduces human error. The growing demand for personalized medicine drives the need for rapid and scalable protein analysis tools. As manufacturing costs decrease, accessibility improves for smaller laboratories. This combination of speed, scalability, and affordability fuels the rapid expansion of the protein microarray segment.

By Reagents Insights

The chromatography reagents segment captured the major share of the global proteomics market in 2025 due to their critical role in sample preparation and protein separation prior to analysis. According to the Association for Biomolecular Resource Facilities, over 90% of mass spectrometry-based proteomic workflows involve some form of liquid chromatography, creating substantial demand for high-purity columns and buffers. This dependency ensures consistent consumption of chromatography consumables across research and clinical settings. According to the Journal of Chromatography A, the resolution of peptide separation has improved by 30% with new stationary phase technologies, enhancing downstream identification rates. These improvements drive laboratories to adopt premium reagents that offer better performance and reproducibility. The complexity of biological samples requires specialized reagents for efficient protein fractionation and cleanup. Researchers prioritize reagents that minimize sample loss and contamination. The recurring nature of chromatography runs generates steady revenue for suppliers. Manufacturers focus on developing robust and durable columns that withstand high pressure and varied pH conditions. The integration of chromatography with automated systems increases throughput and reduces manual handling. As proteomic studies become larger in scale, the volume of reagents used increases proportionally. This fundamental requirement for separation science sustains the dominance of chromatography reagents in the market.

However, the immunoassay reagents segment is anticipated to record a prominent CAGR of 14.4% over the forecast period in the global market owing to the rising demand for specific protein detection in clinical diagnostics. According to the Clinical Chemistry journal, immunoassays account for over 60% of routine clinical laboratory tests for protein markers, driving high-volume consumption of antibodies and detection kits. This widespread use in hospitals and diagnostic centers creates a robust market for high-quality reagents. According to the American Association for Clinical Chemistry, the development of multiplex immunoassays has increased testing efficiency by 40%, allowing for simultaneous measurement of multiple biomarkers. These advancements encourage the adoption of sophisticated reagent panels for complex disease profiling. The shift toward point-of-care testing requires stable and easy-to-use immunoassay components. Pharmaceutical companies utilize these reagents for pharmacokinetic studies and target validation. The increasing prevalence of chronic diseases necessitates regular monitoring of protein levels. Manufacturers are investing in recombinant antibody technologies to improve specificity and reduce batch variability. The expansion of companion diagnostics further boosts demand for validated immunoassay reagents. As personalized medicine becomes more prevalent, the need for precise protein quantification grows,d accelerating market expansion.

By Application Insights

The drug discovery segment accounted for the largest share of the global market in 2025 due to the critical role of protein analysis in identifying and validating therapeutic targets. According to the Pharmaceutical Research and Manufacturers of America, over 70% of new drug candidates fail in clinical trials due to lack of efficacy or safety issues, highlighting the need for better early-stage screening tools. Proteomics provides insights into drug mechanisms of action and potential off-target effects, reducing attrition rates. According to the Nature Reviews Drug Discovery journal, proteomic profiling has contributed to the approval of 25% of new molecular entities in the past decade by identifying novel biomarkers. These successes encourage pharmaceutical companies to integrate proteomics into their core discovery pipelines. The ability to monitor protein expression changes in response to treatment helps optimize dosing regimens. Academic collaborations with industry further drive the adoption of advanced proteomic technologies. The shift toward targeted therapies requires a detailed understanding of protein pathways. High-throughput screening platforms enable rapid evaluation of large compound libraries. As drug development costs rise, the value of proteomics in de-risking projects increases. This strategic importance ensures sustained investment in proteomic applications for drug discovery.

On the other hand, the diagnostics segment is estimated to register a CAGR of 16.4% over the forecast period in the global market owing to the emergence of protein-based biomarkers for early disease detection. According to the Centers for Disease Control and Prevention, early diagnosis can reduce healthcare costs by up to 30% for chronic conditions, driving interest in proteomic diagnostic tests. This economic benefit encourages payers to cover innovative diagnostic assays. According to the Clinical Proteomic Tumor Analysis Consortium, proteomic signatures can distinguish between cancer subtypes with 90% accuracy, enabling personalized treatment strategies. These clinical validations support regulatory approvals for new diagnostic kits. The rise of liquid biopsy techniques relies heavily on proteomic analysis of circulating proteins. Hospitals are adopting multiplex protein assays for comprehensive patient profiling. The integration of proteomics with electronic health records facilitates data-driven clinical decisions. Point-of-care devices utilizing protein markers are gaining traction in emergency settings. As awareness of preventive healthcare grows, demand for sensitive diagnostic tools increases. This transition from research to clinical routine drives rapid market expansion in the diagnostics sector.

COUNTRY LEVEL ANALYSIS

North America Proteomics Market Analysis

North America held the dominant share of the global proteomics market in 2025 and is projected to maintain strong leadership and consistent expansion over the next few years due to its advanced research infrastructure and high healthcare expenditure. According to the National Institutes of Health, the United States accounts for nearly 40% of global biomedical research funding, supporting extensive proteomic studies and instrument procurement. This financial backing drives innovation and adoption of cutting-edge technologies. According to the Food and Drug Administration, the agency has established clear regulatory pathways for proteomic-based diagnostics, encouraging the commercialization of new products. This supportive environment attracts investment from pharmaceutical and biotechnology companies. The presence of major instrument manufacturers and academic centers fosters collaboration and technology transfer. High prevalence of chronic diseases drives demand for proteomic applications in drug discovery and diagnostics. The region leads in integrating artificial intelligence with proteomic data analysis. Strong intellectual property protection encourages innovation and product development. North America remains the primary hub for proteomic research and commercial activity, setting trends for the rest of the world.

Europe Proteomics Market Analysis

Europe is expected to experience steady growth and robust collaborative advancements over the coming years due to strong collaborative research networks and stringent regulatory standards. According to the European Commission, Horizon Europe has allocated over 1 billion euros for life sciences research, including proteomics initiatives aimed at understanding complex diseases. This funding supports multi-center studies and infrastructure development across member states. According to the European Medicines Agency, the agency emphasizes the importance of biomarker validation for drug approval, driving adoption of standardized proteomic workflows. Countries like Germany and the United Kingdom have well-established biotechnology sectors with high utilization of proteomic technologies. The region focuses on sustainability and ethical considerations in research practices. Collaborative projects among universities and industry partners enhance knowledge sharing. The aging population increases demand for proteomic applications in neurodegenerative disease research. While budget constraints exist in some countries, the overall commitment to scientific excellence sustains market growth. Europe continues to be a key player in setting global standards for proteomic quality and reproducibility.

Asia-Pacific Proteomics Market Analysis

Asia-Pacific is anticipated to witness accelerated adoption and dynamic market expansion in the near future owing to the increasing government investment in biotechnology and healthcare. According to the Ministry of Science and Technology in China, research and development spending in life sciences has grown by 15% annually, enabling the acquisition of advanced proteomic instruments. This financial growth allows universities and hospitals to upgrade their analytical capabilities. According to the Indian Department of Biotechnology, national initiatives for precision medicine are driving demand for proteomic services in clinical settings. The large patient population provides ample samples for biomarker discovery studies. Local manufacturers are emerging to provide cost-effective reagents and equipment. Japan and South Korea lead in technological innovation and adoption of automated proteomic platforms. The rise of contract research organizations in the region supports global pharmaceutical companies. Increasing awareness of personalized medicine drives adoption in private healthcare sectors. As infrastructure improves and the skilled workforce expands, the Asia-Pacific market is poised for substantial growth and integration into global supply chains.

Latin America Proteomics Market Analysis

Latin America is projected to display gradual development and steady market integration over the upcoming period due to the gradual improvements in research capacity and healthcare access. According to the Pan American Health Organization, several countries in the region are strengthening their laboratory networks to support infectious disease surveillance and chronic disease management. This initiative drives demand for basic proteomic tools and reagents. According to the Brazilian Ministry of Health, the ministry has initiated programs to support local biotechnology development, fostering a nascent proteomics ecosystem. While advanced instrumentation adoption is limited to major academic centers, demand for outsourcing services is increasing. Economic challenges remain a barrier to rapid growth, but international collaborations help bridge technology gaps. The high burden of tropical diseases creates specific needs for proteomic research. Regional partnerships with global instrument providers facilitate training and equipment access. The focus on improving public health outcomes drives government interest in modernizing diagnostic capabilities. Latin America is gradually integrating into the global proteomics landscape with potential for future acceleration as economic conditions stabilize.

Middle East and Africa Proteomics Market Analysis

Middle East and Africa is poised for consistent upward momentum and strategic healthcare development in the foreseeable future owing to strategic healthcare investments. According to the Gulf Cooperation Council, countries like Saudi Arabia and the United Arab Emirates are investing billions in healthcare transformation projects that include genomics and proteomics centers. These initiatives lay the groundwork for advanced biological research and personalized medicine. According to the African Union, the union has launched initiatives to strengthen health security, which may eventually encompass proteomic capabilities for disease monitoring. Currently, the region relies heavily on imports for instruments and reagents due to limited local manufacturing. However, growing awareness of noncommunicable diseases is raising interest in proteomic diagnostics. International collaborations with European and American institutions are facilitating knowledge transfer. Regulatory bodies are beginning to develop guidelines for laboratory standards. The high prevalence of genetic disorders in certain populations creates targeted demand for research. As economic diversification efforts continue, the region may see increased investment in specialized research infrastructure. The market remains in early stages but shows signs of long-term potential as healthcare systems mature.

COMPETITIVE LANDSCAPE

The competition in the Proteomics Market is characterized by intense rivalry among established life sciences giants and emerging technology specialists. Major players compete on the basis of instrument performance, data accuracy, and comprehensive service offerings. The market features a mix of large multinational corporations and niche manufacturers focusing on specific analytical techniques such as mass spectrometry or microarrays. Continuous innovation drives competitive dynamics as companies strive to launch devices with improved resolution and faster processing speeds. Regulatory hurdles create barriers to entry but also encourage high standards of quality and reproducibility. Price competition remains moderate due to the specialized nature of the equipment and the need for proven reliability. Collaborative efforts between manufacturers and research institutions shape product development priorities and adoption patterns. Intellectual property disputes occasionally arise as firms protect their proprietary algorithms and hardware designs. The landscape is further influenced by consolidation activities where larger entities acquire smaller firms to broaden their technological capabilities. This dynamic environment pushes companies to differentiate through unique value propositions and strong technical support networks, ensuring sustained growth and market relevance.

KEY MARKET PLAYERS

Some of the companies that are playing a dominating role in the Global Proteomics Market include:

• Agilent Technologies Inc.
• Bio-Rad Laboratories, Inc.
• Bruker Corporation
• Danaher Corporation
• GE Healthcare
• Luminex Corporation
• Merck KGaA
• PerkinElmer Inc.
• Thermo Fisher Scientific, Inc.
• Waters Corporation

TOP LEADING PLAYERS IN THE MARKET

• Thermo Fisher Scientific Inc maintains a leading position in the Proteomics Market through its comprehensive portfolio of mass spectrometry instruments and reagents. The company offers advanced Orbitrap technology that delivers high resolution and sensitivity for complex protein analysis. Thermo Fisher recently launched new software platforms that integrate artificial intelligence to streamline data processing and interpretation. These innovations enhance workflow efficiency for researchers in academic and pharmaceutical settings. The company actively collaborates with global research institutions to develop standardized proteomic protocols. By expanding its manufacturing capabilities, Thermo Fisher ensures a consistent supply of critical consumables. Its strong distribution network provides reliable access to cutting-edge technologies worldwide. The company continues to invest in research to advance precision medicine applications. This commitment to innovation reinforces its reputation as a trusted partner for proteomic scientists seeking robust analytical solutions.
• Waters Corporation contributes significantly to the market by offering high-performance liquid chromatography systems and mass spectrometers tailored for proteomic applications. The company emphasizes robust engineering to deliver instruments that ensure reproducibility and accuracy in protein separation. Waters recently introduced new column technologies designed to improve peptide resolution and reduce analysis time. These advancements help researchers achieve deeper proteome coverage with greater efficiency. The company engages in strategic partnerships with bioinformatics firms to enhance data analysis capabilities. Waters focuses on providing comprehensive training and support services to maximize instrument utilization. Its commitment to quality control ensures consistent performance across diverse laboratory environments. The company supports healthcare providers with validated methods for clinical biomarker discovery. This customer-centric approach strengthens its position as a key provider of essential proteomic tools in the region.
• Danaher Corporation plays a vital role in the market through its subsidiary AB Sciex, which specializes in tandem mass spectrometry technologies. The company leverages its extensive experience in life sciences to develop instruments that offer superior sensitivity for low-abundance proteins. Danaher recently expanded its product line with next-generation quantitative proteomics systems designed for high-throughput screening. These enhancements enable faster drug discovery and more accurate clinical diagnostics. The company actively participates in multicenter studies to generate real-world evidence supporting its technologies. Danaher also strengthens its market position through targeted acquisitions of innovative software companies. This strategy allows the integration of advanced data analytics into its hardware offerings. By focusing on end-to-end solutions, Danaher continues to influence standards in proteomic research and development across the globe.

TOP STRATEGIES USED BY KEY MARKET PARTICIPANTS

Key players in the Proteomics Market primarily focus on technological innovation and strategic collaborations to maintain competitive advantage. Companies invest heavily in research and development to create instruments with enhanced sensitivity and throughput capabilities. Launching integrated software solutions allows firms to address complex data analysis challenges and improve user experience. Strategic partnerships with academic institutions facilitate clinical validation and generate robust data supporting device efficacy. Mergers and acquisitions serve as another critical strategy enabling companies to expand their product portfolios and enter new therapeutic areas. By acquiring specialized biotech firms, established players integrate novel reagents and assay kits into their existing lines. Regulatory compliance is pursued through rigorous testing and engagement with health authorities. Companies also prioritize scientist education and training programs to ensure proper instrument utilization and build brand loyalty. These combined efforts help manufacturers strengthen their market presence and respond effectively to evolving research demands in the region.

GLOBAL PROTEOMICS MARKET NEWS 

• Proteomics succeeded where genomics had failed in this case. German doctors used a new neutrophil proteome database to diagnose two children with severe congenital neutropenia whose typical sequencing had failed.
• Researchers from the University of Copenhagen have studied large amounts of data from tissue samples of the skin to map its molecules and functions. As a result, they have been able to create a skin atlas using the data. This will help scientists understand the differences between dead skin and living skin in greater detail, allowing for better diagnosis of various diseases.
• A group of scientists from the Centre for Genomic Regulation (CRG) in Barcelona, led by the ICREA Research Professor Luciano di Croce, Sergio Aranda, lead author and co-leader of the study, and Eduard Sabidó, head of the CRG/UPF Proteomics Unit, have identified a molecular mechanism that regulates stem cell division speed. Furthermore, this study found that AHCY protein plays an essential and irreplaceable role in human fertility.

MARKET SEGMENTATION

This research report on the global proteomics market has been segmented and sub-segmented based on the Instrument Type, Reagents, Software & Service , Application and Region.

 By Instrument Type

• Protein Microarrays
• Spectroscopy
• X-Ray Crystallography
• Chromatography
• Electrophoresis
• Surface Plasmon Resonance
• Protein Fractionation

By Reagents

• Protein Microarray Reagents
• X-Ray Crystallography Reagents
• Spectroscopy Reagents
• Chromatography Reagents
• Electrophoresis Reagents
• Immunoassay Reagents

By Software & Service

• Analytical Laboratory Services
• Data Analysis & Maintenance
• Quantitation Services

By Application

• Diagnostics
• Drug Discovery
• Other Proteomic Applications

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa